{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:52:28Z","timestamp":1794653548099,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARFD-16-442821"],"award-info":[{"award-number":["AARFD-16-442821"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Allelic variation to the\n                    <jats:italic>APOE<\/jats:italic>\n                    gene confers the greatest genetic risk for sporadic Alzheimer\u2019s disease (AD). Independent of genotype, low abundance of apolipoprotein E (apoE), is characteristic of AD CSF, and predicts cognitive decline. The mechanisms underlying the genotype and apoE level risks are uncertain. Recent fluid and imaging biomarker studies have revealed an unexpected link between apoE and brain iron, which also forecasts disease progression, possibly through ferroptosis, an iron-dependent regulated cell death pathway. Here, we report that apoE is a potent inhibitor of ferroptosis (EC\n                    <jats:sub>50<\/jats:sub>\n                    \u2009\u2248\u200910\u2009nM; N27 neurons). We demonstrate that apoE signals to activate the PI3K\/AKT pathway that then inhibits the autophagic degradation of ferritin (ferritinophagy), thus averting iron-dependent lipid peroxidation. Using postmortem inferior temporal brain cortex tissue from deceased subjects from the Rush Memory and Aging Project (MAP) (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009608), we found that the association of iron with pathologically confirmed clinical Alzheimer\u2019s disease was stronger among those with the adverse\n                    <jats:italic>APOE<\/jats:italic>\n                    -\u03b54 allele. While protection against ferroptosis did not differ between apoE isoforms in vitro, other features of \u03b54 carriers, such as low abundance of apoE protein and higher levels of polyunsaturated fatty acids (which fuel ferroptosis) could mediate the \u03b54 allele\u2019s heighted risk of AD. These data support ferroptosis as a putative pathway to explain the major genetic risk associated with late onset AD.\n                  <\/jats:p>","DOI":"10.1038\/s41380-022-01568-w","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T11:04:32Z","timestamp":1651143872000},"page":"211-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0792-8728","authenticated-orcid":false,"given":"Abdel Ali","family":"Belaidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-4983","authenticated-orcid":false,"given":"Shashank","family":"Masaldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Southon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambili T.","family":"Appukuttan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Portbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-1962","authenticated-orcid":false,"given":"Peng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-6653","authenticated-orcid":false,"given":"Puja","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-1665","authenticated-orcid":false,"given":"Sue E.","family":"Leurgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-5612","authenticated-orcid":false,"given":"Marcus","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-9069","authenticated-orcid":false,"given":"Ashley I.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3479-2427","authenticated-orcid":false,"given":"Scott","family":"Ayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"1568_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12031-016-0839-z","volume":"60","author":"L Mahoney-Sanchez","year":"2016","unstructured":"Mahoney-Sanchez L, Belaidi AA, Bush AI, Ayton S. The complex role of apolipoprotein E in Alzheimer\u2019s disease: An overview and update. J Mol Neurosci. 2016;60:325\u201335.","journal-title":"J Mol Neurosci"},{"key":"1568_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7760","volume":"6","author":"S Ayton","year":"2015","unstructured":"Ayton S, Faux NG, Bush AI, Alzheimer\u2019s Disease Neuroimaging I. Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE. Nat Commun. 2015;6:6760.","journal-title":"Nat Commun"},{"key":"1568_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-013-1236-0","volume":"127","author":"JB Toledo","year":"2014","unstructured":"Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, et al. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 2014;127:621\u201332.","journal-title":"Acta Neuropathol"},{"key":"1568_CR4","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1093\/hmg\/dds296","volume":"21","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer\u2019s disease. Hum Mol Genet. 2012;21:4558\u201371.","journal-title":"Hum Mol Genet"},{"key":"1568_CR5","doi-asserted-by":"publisher","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","volume":"28","author":"DR Riddell","year":"2008","unstructured":"Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28:11445\u201353.","journal-title":"J Neurosci"},{"key":"1568_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep35514","volume":"6","author":"JM van Bergen","year":"2016","unstructured":"van Bergen JM, Li X, Hua J, Schreiner SJ, Steininger SC, Quevenco FC, et al. Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Sci Rep. 2016;6:35514.","journal-title":"Sci Rep"},{"key":"1568_CR7","first-page":"e12002","volume":"12","author":"SM Kagerer","year":"2020","unstructured":"Kagerer SM, van Bergen JMG, Li X, Quevenco FC, Gietl AF, Studer S, et al. APOE4 moderates effects of cortical iron on synchronized default mode network activity in cognitively healthy old-aged adults. Alzheimers Dement (Amst). 2020;12:e12002.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1568_CR8","first-page":"123","volume":"38","author":"C Colombelli","year":"2014","unstructured":"Colombelli C, Aoun M, Tiranti V. Defective lipid metabolism in neurodegeneration with brain iron accumulation (NBIA) syndromes: Not only a matter of iron. J Inherited Metab. Dis. 2014;38:123\u201336.","journal-title":"Dis."},{"key":"1568_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jnc.13425","volume":"139","author":"AA Belaidi","year":"2016","unstructured":"Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer\u2019s disease and Parkinson\u2019s disease: Targets for therapeutics. J. Neurochem. 2016;139:179\u201397.","journal-title":"J. Neurochem."},{"key":"1568_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00005053-195308000-00001","volume":"118","author":"L Goodman","year":"1953","unstructured":"Goodman L. Alzheimer\u2019s disease; A clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis. 1953;118:97\u2013130.","journal-title":"J Nerv Ment Dis"},{"key":"1568_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1471-4159.1960.tb13369.x","volume":"5","author":"B Hallgren","year":"1960","unstructured":"Hallgren B, Sourander P. The non-haemin iron in the cerebral cortex in Alzheimer\u2019s disease. J Neurochem. 1960;5:307\u201310.","journal-title":"J Neurochem"},{"key":"1568_CR12","doi-asserted-by":"publisher","first-page":"116808","DOI":"10.1016\/j.neuroimage.2020.116808","volume":"215","author":"WM Bulk","year":"2020","unstructured":"Bulk M, Abdelmoula WM, Geut H, Wiarda W, Ronen I, Dijkstra J, et al. Quantitative MRI and laser ablation-inductively coupled plasma-mass spectrometry imaging of iron in the frontal cortex of healthy controls and Alzheimer\u2019s disease patients. Neuroimage. 2020;215:116808.","journal-title":"Neuroimage."},{"key":"1568_CR13","doi-asserted-by":"publisher","first-page":"eabf6707","DOI":"10.1126\/sciadv.abf6707","volume":"7","author":"J Everett","year":"2021","unstructured":"Everett J, Lermyte F, Brooks J, Tjendana-Tjhin V, Plascencia-Villa G, Hands-Portman I, et al. Biogenic metallic elements in the human brain? Sci Adv. 2021;7:eabf6707.","journal-title":"Sci Adv."},{"key":"1568_CR14","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1038\/s41380-019-0375-7","volume":"25","author":"S Ayton","year":"2020","unstructured":"Ayton S, Wang Y, Diouf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry. 2020;25:2932\u201341.","journal-title":"Mol Psychiatry"},{"key":"1568_CR15","doi-asserted-by":"crossref","unstructured":"Ayton S, Portbury S, Kalinowski P, Agarwal P, Diouf I, Schneider JA, et al. Regional brain iron associated with deterioration in Alzheimer\u2019s disease: A large cohort study and theoretical significance. Alzheimer\u2019s Dementia. 2021;17:1244\u201356.","DOI":"10.1002\/alz.12282"},{"key":"1568_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1136\/jnnp-2017-316551","volume":"89","author":"S Ayton","year":"2018","unstructured":"Ayton S, Diouf I, Bush AI. Alzheimer\u2019s disease Neuroimaging I. Evidence that iron accelerates Alzheimer\u2019s pathology: a CSF biomarker study. J Neurol Neurosurg Psychiatry. 2018;89:456\u201360.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1568_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.nbd.2018.12.010","volume":"124","author":"I Diouf","year":"2019","unstructured":"Diouf I, Fazlollahi A, Bush AI, Ayton S. Alzheimer\u2019s disease Neuroimaging I. Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying beta-amyloid pathology. Neurobiol Dis. 2019;124:335\u20139.","journal-title":"Neurobiol Dis"},{"key":"1568_CR18","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/brain\/awx137","volume":"140","author":"S Ayton","year":"2017","unstructured":"Ayton S, Fazlollahi A, Bourgeat P, Raniga P, Ng A, Lim YY, et al. Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain: J Neurol. 2017;140:2112\u20139.","journal-title":"Brain: J Neurol"},{"key":"1568_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1001\/jamaneurol.2016.4406","volume":"74","author":"S Ayton","year":"2017","unstructured":"Ayton S, Faux NG, Bush AI. Association of cerebrospinal fluid ferritin level with preclinical cognitive decline in APOE-epsilon4 Carriers. JAMA Neurol. 2017;74:122\u20135.","journal-title":"JAMA Neurol"},{"key":"1568_CR20","doi-asserted-by":"publisher","first-page":"101904","DOI":"10.1016\/j.pneurobio.2020.101904","volume":"198","author":"S Ayton","year":"2021","unstructured":"Ayton S, Janelidze S, Roberts B, Palmqvist S, Kalinowski P, Diouf I, et al. Acute phase markers in CSF reveal inflammatory changes in Alzheimer\u2019s disease that intersect with pathology, APOE epsilon4, sex and age. Prog Neurobiol. 2021;198:101904.","journal-title":"Prog Neurobiol"},{"key":"1568_CR21","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1111\/bph.14567","volume":"176","author":"S Nikseresht","year":"2019","unstructured":"Nikseresht S, Bush AI, Ayton S. Treating Alzheimer\u2019s disease by targeting iron. Br J Pharm. 2019;176:3622\u201335.","journal-title":"Br J Pharm"},{"key":"1568_CR22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"1568_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"HF Yan","year":"2021","unstructured":"Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi AA, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021;6:49.","journal-title":"Signal Transduct Target Ther"},{"key":"1568_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.devcel.2020.06.019","volume":"54","author":"MA Perez","year":"2020","unstructured":"Perez MA, Magtanong L, Dixon SJ, Watts JL. Dietary Lipids Induce Ferroptosis in Caenorhabditiselegans and Human Cancer Cells. Dev Cell. 2020;54:447\u201354 e4.","journal-title":"Dev Cell"},{"key":"1568_CR25","doi-asserted-by":"crossref","unstructured":"Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, et al. Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell Chem Biol. 2019;26:420\u201332 e9.","DOI":"10.1016\/j.chembiol.2018.11.016"},{"key":"1568_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat cell Biol. 2014;16:1180\u201391.","journal-title":"Nat cell Biol"},{"key":"1568_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2017.11.048","volume":"172","author":"I Ingold","year":"2018","unstructured":"Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, et al. Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell 2018;172:409\u201322 e21.","journal-title":"Cell"},{"key":"1568_CR28","doi-asserted-by":"crossref","unstructured":"Tuo QZ, Masaldan S, Southon A, Mawal C, Ayton S, Bush AI, et al. Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemia-Reperfusion Injury. Neurotherapeutics. 2021.","DOI":"10.1007\/s13311-021-01111-9"},{"key":"1568_CR29","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.biopsych.2015.04.005","volume":"78","author":"PK Mandal","year":"2015","unstructured":"Mandal PK, Saharan S, Tripathi M, Murari G. Brain glutathione levels-a novel biomarker for mild cognitive impairment and Alzheimer\u2019s disease. Biol psychiatry. 2015;78:702\u201310.","journal-title":"Biol psychiatry"},{"key":"1568_CR30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3174\/ajnr.A5143","volume":"38","author":"GC Chiang","year":"2017","unstructured":"Chiang GC, Mao X, Kang G, Chang E, Pandya S, Vallabhajosula S, et al. Relationships among cortical glutathione levels, brain amyloidosis, and memory in healthy older adults investigated in vivo with (1)H-MRS and Pittsburgh Compound-B PET. AJNR Am J Neuroradiol. 2017;38:1130\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1568_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/NEN.0b013e3181cb5af4","volume":"69","author":"MA Ansari","year":"2010","unstructured":"Ansari MA, Scheff SW. Oxidative Stress in the Progression of Alzheimer Disease in the Frontal Cortex. J Neuropathol Exp Neurol. 2010;69:155\u201367.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1568_CR32","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","volume":"73","author":"M Gao","year":"2019","unstructured":"Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB, et al. Role of Mitochondria in Ferroptosis. Mol Cell. 2019;73:354\u201363 e3.","journal-title":"Mol Cell"},{"key":"1568_CR33","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014;3:e02523.","journal-title":"Elife"},{"key":"1568_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature13148","volume":"509","author":"JD Mancias","year":"2014","unstructured":"Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 2014;509:105\u20139.","journal-title":"Nature"},{"key":"1568_CR35","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1101\/gad.1256804","volume":"18","author":"J Brugarolas","year":"2004","unstructured":"Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893\u2013904.","journal-title":"Genes Dev"},{"key":"1568_CR36","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.freeradbiomed.2010.02.016","volume":"48","author":"MA Bradley","year":"2010","unstructured":"Bradley MA, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med. 2010;48:1570\u20136.","journal-title":"Free Radic Biol Med"},{"key":"1568_CR37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neurobiolaging.2005.06.004","volume":"27","author":"TI Williams","year":"2006","unstructured":"Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer\u2019s disease. Neurobiol aging. 2006;27:1094\u20139.","journal-title":"Neurobiol aging"},{"key":"1568_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","volume":"125","author":"TJ Montine","year":"2001","unstructured":"Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch Pathol Lab Med. 2001;125:510\u20132.","journal-title":"Arch Pathol Lab Med"},{"key":"1568_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.nbd.2007.12.007","volume":"30","author":"T Reed","year":"2008","unstructured":"Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer\u2019s disease. Neurobiol Dis. 2008;30:107\u201320.","journal-title":"Neurobiol Dis"},{"key":"1568_CR40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3233\/JAD-2010-091723","volume":"21","author":"I Baldeiras","year":"2010","unstructured":"Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, et al. Oxidative damage and progression to Alzheimer\u2019s disease in patients with mild cognitive impairment. J Alzheimer\u2019s Dis: JAD. 2010;21:1165\u201377.","journal-title":"J Alzheimer\u2019s Dis: JAD"},{"key":"1568_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-2-2","volume":"2","author":"G Casadesus","year":"2007","unstructured":"Casadesus G, Smith MA, Basu S, Hua J, Capobianco DE, Siedlak SL, et al. Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegeneration. 2007;2:2.","journal-title":"Mol Neurodegeneration"},{"key":"1568_CR42","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1148\/radiol.2020192541","volume":"296","author":"A Damulina","year":"2020","unstructured":"Damulina A, Pirpamer L, Soellradl M, Sackl M, Tinauer C, Hofer E, et al. Cross-sectional and longitudinal assessment of brain iron level in Alzheimer disease using 3-T MRI. Radiology 2020;296:619\u201326.","journal-title":"Radiology"},{"key":"1568_CR43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bph.14881","volume":"177","author":"A Southon","year":"2020","unstructured":"Southon A, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, et al. Cu(II) (atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. Br J Pharm. 2020;177:656\u201367.","journal-title":"Br J Pharm"},{"key":"1568_CR44","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/1873-3468.13428","volume":"593","author":"E Hubin","year":"2019","unstructured":"Hubin E, Verghese PB, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 2019;593:1144\u201353.","journal-title":"FEBS Lett"},{"key":"1568_CR45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3233\/JAD-191017","volume":"74","author":"N Tomaszewski","year":"2020","unstructured":"Tomaszewski N, He X, Solomon V, Lee M, Mack WJ, Quinn JF, et al. Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer\u2019s Disease Cooperative Study-Sponsored DHA Clinical Trial. J Alzheimer\u2019s Dis: JAD. 2020;74:975\u201390.","journal-title":"J Alzheimer\u2019s Dis: JAD"},{"key":"1568_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.18632\/aging.101203","volume":"9","author":"L Abdullah","year":"2017","unstructured":"Abdullah L, Evans JE, Emmerich T, Crynen G, Shackleton B, Keegan AP, et al. APOE epsilon4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment\/Alzheimer\u2019s Disease. Aging (Albany NY). 2017;9:964\u201385.","journal-title":"Aging (Albany NY)"},{"key":"1568_CR47","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1017\/S0007114513001268","volume":"110","author":"R Chouinard-Watkins","year":"2013","unstructured":"Chouinard-Watkins R, Rioux-Perreault C, Fortier M, Tremblay-Mercier J, Zhang Y, Lawrence P, et al. Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoE epsilon4 allele. Br J Nutr. 2013;110:1751\u20139.","journal-title":"Br J Nutr"},{"key":"1568_CR48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021\u201332.","journal-title":"Cell Res"},{"key":"1568_CR49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.physbeh.2011.04.018","volume":"105","author":"L Shen","year":"2011","unstructured":"Shen L, Wang DQ, Tso P, Jandacek RJ, Woods SC, Liu M. Apolipoprotein E reduces food intake via PI3K\/Akt signaling pathway in the hypothalamus. Physiol Behav. 2011;105:124\u20138.","journal-title":"Physiol Behav"},{"key":"1568_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74\u201388.","journal-title":"Nat Rev Cancer"},{"key":"1568_CR51","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1212\/WNL.0b013e318211c352","volume":"76","author":"VB Gupta","year":"2011","unstructured":"Gupta VB, Laws SM, Villemagne VL, Ames D, Bush AI, Ellis KA, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 2011;76:1091\u20138.","journal-title":"Neurology"},{"key":"1568_CR52","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1074\/mcp.M112.018861","volume":"11","author":"R Simon","year":"2012","unstructured":"Simon R, Girod M, Fonbonne C, Salvador A, Clement Y, Lanteri P, et al. Total ApoE and ApoE4 isoform assays in an Alzheimer\u2019s disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteom. 2012;11:1389\u2013403.","journal-title":"Mol Cell Proteom"},{"key":"1568_CR53","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1097\/00001756-199412000-00032","volume":"5","author":"K Blennow","year":"1994","unstructured":"Blennow K, Hesse C, Fredman P. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer\u2019s disease. Neuroreport 1994;5:2534\u20136.","journal-title":"Neuroreport"},{"key":"1568_CR54","doi-asserted-by":"publisher","first-page":"11657","DOI":"10.1021\/bi000099m","volume":"39","author":"JA Morrow","year":"2000","unstructured":"Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B, et al. Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. Biochemistry 2000;39:11657\u201366.","journal-title":"Biochemistry"},{"key":"1568_CR55","doi-asserted-by":"publisher","first-page":"50380","DOI":"10.1074\/jbc.M204898200","volume":"277","author":"JA Morrow","year":"2002","unstructured":"Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, et al. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. J Biol Chem. 2002;277:50380\u20135.","journal-title":"J Biol Chem"},{"key":"1568_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nbd.2015.06.016","volume":"81","author":"H Xu","year":"2015","unstructured":"Xu H, Gupta VB, Martins IJ, Martins RN, Fowler CJ, Bush AI, et al. Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way. Neurobiol Dis. 2015;81:38\u201348.","journal-title":"Neurobiol Dis"},{"key":"1568_CR57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer\u2019s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163\u20136.","journal-title":"Brain Res"},{"key":"1568_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81\u201390.","journal-title":"Nat Chem Biol"},{"key":"1568_CR59","doi-asserted-by":"publisher","first-page":"eaaz4564","DOI":"10.1126\/scitranslmed.aaz4564","volume":"13","author":"G Sienski","year":"2021","unstructured":"Sienski G, Narayan P, Bonner JM, Kory N, Boland S, Arczewska AA, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med. 2021;13:eaaz4564.","journal-title":"Sci Transl Med"},{"key":"1568_CR60","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","volume":"304","author":"JF Quinn","year":"2010","unstructured":"Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 2010;304:1903\u201311.","journal-title":"JAMA"},{"key":"1568_CR61","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1212\/01.wnl.0000278116.37320.52","volume":"69","author":"P Barberger-Gateau","year":"2007","unstructured":"Barberger-Gateau P, Raffaitin C, Letenneur L, Berr C, Tzourio C, Dartigues JF, et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007;69:1921\u201330.","journal-title":"Neurology"},{"key":"1568_CR62","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1212\/01.wnl.0000183148.34197.2e","volume":"65","author":"TL Huang","year":"2005","unstructured":"Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005;65:1409\u201314.","journal-title":"Neurology"},{"key":"1568_CR63","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/ajcn\/85.4.1103","volume":"85","author":"MA Beydoun","year":"2007","unstructured":"Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: The Atherosclerosis risk in communities study. Am J Clin Nutr. 2007;85:1103\u201311.","journal-title":"Am J Clin Nutr"},{"key":"1568_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/ajcn\/87.2.449","volume":"87","author":"LJ Whalley","year":"2008","unstructured":"Whalley LJ, Deary IJ, Starr JM, Wahle KW, Rance KA, Bourne VJ, et al. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: An observational follow-up study in late adulthood. Am J Clin Nutr. 2008;87:449\u201354.","journal-title":"Am J Clin Nutr"},{"key":"1568_CR65","doi-asserted-by":"publisher","first-page":"2317 e13","DOI":"10.1016\/j.neurobiolaging.2010.03.020","volume":"32","author":"C Samieri","year":"2011","unstructured":"Samieri C, Feart C, Proust-Lima C, Peuchant E, Dartigues JF, Amieva H, et al. omega-3 fatty acids and cognitive decline: Modulation by ApoEepsilon4 allele and depression. Neurobiol Aging. 2011;32:2317 e13\u201322.","journal-title":"Neurobiol Aging"},{"key":"1568_CR66","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1006\/nbdi.1999.0273","volume":"7","author":"C Ramassamy","year":"2000","unstructured":"Ramassamy C, Averill D, Beffert U, Theroux L, Lussier-Cacan S, Cohn JS, et al. Oxidative insults are associated with apolipoprotein E genotype in Alzheimer\u2019s disease brain. Neurobiol Dis. 2000;7:23\u201337.","journal-title":"Neurobiol Dis"},{"key":"1568_CR67","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0891-5849(99)00102-1","volume":"27","author":"C Ramassamy","year":"1999","unstructured":"Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer\u2019s disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999;27:544\u201353.","journal-title":"Free Radic Biol Med"},{"key":"1568_CR68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","volume":"66","author":"B Zhou","year":"2020","unstructured":"Zhou B, Liu J, Kang R, Klionsky DJ, Kroemer G, Tang D. Ferroptosis is a type of autophagy-dependent cell death. Semin Cancer Biol. 2020;66:89\u2013100.","journal-title":"Semin Cancer Biol"},{"key":"1568_CR69","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jalz.2017.07.754","volume":"14","author":"PA Parcon","year":"2018","unstructured":"Parcon PA, Balasubramaniam M, Ayyadevara S, Jones RA, Liu L, Shmookler Reis RJ, et al. Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimers Dement. 2018;14:230\u201342.","journal-title":"Alzheimers Dement"},{"key":"1568_CR70","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3233\/JAD-151101","volume":"51","author":"S Simonovitch","year":"2016","unstructured":"Simonovitch S, Schmukler E, Bespalko A, Iram T, Frenkel D, Holtzman DM, et al. Impaired Autophagy in APOE4 Astrocytes. J Alzheimer\u2019s Dis: JAD. 2016;51:915\u201327.","journal-title":"J Alzheimer\u2019s Dis: JAD"},{"key":"1568_CR71","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2174\/156720512801322663","volume":"9","author":"DA Bennett","year":"2012","unstructured":"Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9:646\u201363.","journal-title":"Curr Alzheimer Res"},{"key":"1568_CR72","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pep.2011.06.011","volume":"79","author":"L Argyri","year":"2011","unstructured":"Argyri L, Skamnaki V, Stratikos E, Chroni A. A simple approach for human recombinant apolipoprotein E4 expression and purification. Protein Expr Purif. 2011;79:251\u20137.","journal-title":"Protein Expr Purif"},{"key":"1568_CR73","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s13311-018-0656-x","volume":"15","author":"AA Belaidi","year":"2018","unstructured":"Belaidi AA, Gunn AP, Wong BX, Ayton S, Appukuttan AT, Roberts BR, et al. Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice. Neurotherapeutics 2018;15:1055\u201362.","journal-title":"Neurotherapeutics"},{"key":"1568_CR74","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1073\/pnas.0712145105","volume":"105","author":"IH Lee","year":"2008","unstructured":"Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA. 2008;105:3374\u20139.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01568-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T05:03:08Z","timestamp":1716440588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1568"],"URL":"https:\/\/doi.org\/10.1038\/s41380-022-01568-w","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AIB is a shareholder in Alterity Biotechnology Ltd, Cogstate Ltd, and Mesoblast Ltd. He is a paid consultant for, and has a profit share interest in, Collaborative Medicinal Development Pty Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}